ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

CIK: 0001845297 · Show all filings

Period: Q4 2020 (Next →)

Filing Date: Feb 16, 2021

Total Value ($000): $169,844 (100.0% shares, 0.0% debt)

Holdings (7)

AVIR ATEA PHARMACEUTICALS INC 64.9%

Value ($000) $110,265 Shares 2,639,178 Est. Cost $32.23 Unrealized 0.0%

LUNG PULMONX CORP 33.9%

Value ($000) $57,517 Shares 833,333 Est. Cost $48.97 Unrealized 0.0%

GNCAQ GENOCEA BIOSCIENCES INC 0.5%

Value ($000) $908 Shares 375,000 Est. Cost $2.28 Unrealized 0.0%

— SYNLOGIC INC 0.3%

Value ($000) $445 Shares 205,906 Est. Cost $2.16 Unrealized —

— AERPIO PHARMACEUTICALS INC 0.2%

Value ($000) $392 Shares 400,000 Est. Cost $0.98 Unrealized —

— IDERA PHARMACEUTICALS INC 0.1%

Value ($000) $206 Shares 56,250 Est. Cost $3.66 Unrealized —

— NABRIVA THERAPEUTICS PLC 0.1%

Value ($000) $111 Shares 45,849 Est. Cost $2.42 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
AVIR	ATEA PHARMACEUTICALS INC	2,639,178	$110,265	64.9%	$32.23	0.0%	COM	04683R106
LUNG	PULMONX CORP	833,333	$57,517	33.9%	$48.97	0.0%	COM	745848101
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$908	0.5%	$2.28	0.0%	COM NEW	372427401
—	SYNLOGIC INC	205,906	$445	0.3%	$2.16	—	COM	87166L100
—	AERPIO PHARMACEUTICALS INC	400,000	$392	0.2%	$0.98	—	COM	00810B105
—	IDERA PHARMACEUTICALS INC	56,250	$206	0.1%	$3.66	—	COM PAR	45168K405
—	NABRIVA THERAPEUTICS PLC	45,849	$111	0.1%	$2.42	—	SHS NEW	G63637113